 | • レポートコード：GIR-2104Z09916 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、神経変性疾患のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。神経変性疾患の種類別市場規模（NMDA、SSRI、ドーパミン阻害剤）、用途別市場規模（パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、アルツハイマー病）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・神経変性疾患の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Novartis、Pfizer、Merck Serono、Biogen Idec、TEVA、UCB、Boehringer Ingelheim、Sanofi、GlaxoSmithKline ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：NMDA、SSRI、ドーパミン阻害剤 ・用途別分析2016年-2026年：パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、アルツハイマー病 ・神経変性疾患の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・神経変性疾患のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・神経変性疾患のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・神経変性疾患の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・神経変性疾患の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Neurodegenerative Disease market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Neurodegenerative Disease size is estimated to be USD 8105.5 million in 2025 from USD 7206 million in 2019, with a change XX% between 2019 and 2020. The global Neurodegenerative Disease market size is expected to grow at a CAGR of 3.0% for the next five years.
Market segmentation
Neurodegenerative Disease market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
NMDA
SSRIs
Dopamine Inhibitors
Market segment by Application, can be divided into
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Market segment by players, this report covers
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Neurodegenerative Disease
1.2 Classification of Neurodegenerative Disease by Type
1.2.1 Overview: Global Neurodegenerative Disease Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Neurodegenerative Disease Revenue Market Share by Type in 2020
1.2.3 NMDA
1.2.4 SSRIs
1.2.5 Dopamine Inhibitors
1.3 Global Neurodegenerative Disease Market by Application
1.3.1 Overview: Global Neurodegenerative Disease Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Global Neurodegenerative Disease Market Size & Forecast
1.5 Global Neurodegenerative Disease Market Size and Forecast by Region
1.5.1 Global Neurodegenerative Disease Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Neurodegenerative Disease Market Size by Region, (2016-2021)
1.5.3 North America Neurodegenerative Disease Market Size and Prospect (2016-2026)
1.5.4 Europe Neurodegenerative Disease Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Neurodegenerative Disease Market Size and Prospect (2016-2026)
1.5.6 South America Neurodegenerative Disease Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Neurodegenerative Disease Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Neurodegenerative Disease Market Drivers
1.6.2 Neurodegenerative Disease Market Restraints
1.6.3 Neurodegenerative Disease Trends Analysis
2 Company Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Neurodegenerative Disease Product and Solutions
2.1.4 Novartis Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Novartis Recent Developments and Future Plans
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Neurodegenerative Disease Product and Solutions
2.2.4 Pfizer Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Pfizer Recent Developments and Future Plans
2.3 Merck Serono
2.3.1 Merck Serono Details
2.3.2 Merck Serono Major Business
2.3.3 Merck Serono Neurodegenerative Disease Product and Solutions
2.3.4 Merck Serono Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Merck Serono Recent Developments and Future Plans
2.4 Biogen Idec
2.4.1 Biogen Idec Details
2.4.2 Biogen Idec Major Business
2.4.3 Biogen Idec Neurodegenerative Disease Product and Solutions
2.4.4 Biogen Idec Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Biogen Idec Recent Developments and Future Plans
2.5 TEVA
2.5.1 TEVA Details
2.5.2 TEVA Major Business
2.5.3 TEVA Neurodegenerative Disease Product and Solutions
2.5.4 TEVA Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 TEVA Recent Developments and Future Plans
2.6 UCB
2.6.1 UCB Details
2.6.2 UCB Major Business
2.6.3 UCB Neurodegenerative Disease Product and Solutions
2.6.4 UCB Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 UCB Recent Developments and Future Plans
2.7 Boehringer Ingelheim
2.7.1 Boehringer Ingelheim Details
2.7.2 Boehringer Ingelheim Major Business
2.7.3 Boehringer Ingelheim Neurodegenerative Disease Product and Solutions
2.7.4 Boehringer Ingelheim Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Boehringer Ingelheim Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Neurodegenerative Disease Product and Solutions
2.8.4 Sanofi Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 GlaxoSmithKline
2.9.1 GlaxoSmithKline Details
2.9.2 GlaxoSmithKline Major Business
2.9.3 GlaxoSmithKline Neurodegenerative Disease Product and Solutions
2.9.4 GlaxoSmithKline Neurodegenerative Disease Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 GlaxoSmithKline Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Neurodegenerative Disease Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Neurodegenerative Disease Players Market Share
3.2.2 Top 10 Neurodegenerative Disease Players Market Share
3.2.3 Market Competition Trend
3.3 Neurodegenerative Disease Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Neurodegenerative Disease Revenue and Market Share by Type (2016-2021)
4.2 Global Neurodegenerative Disease Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Neurodegenerative Disease Revenue Market Share by Application (2016-2021)
5.2 Neurodegenerative Disease Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Neurodegenerative Disease Revenue by Type (2016-2026)
6.2 North America Neurodegenerative Disease Revenue by Application (2016-2026)
6.3 North America Neurodegenerative Disease Market Size by Country
6.3.1 North America Neurodegenerative Disease Revenue by Country (2016-2026)
6.3.2 United States Neurodegenerative Disease Market Size and Forecast (2016-2026)
6.3.3 Canada Neurodegenerative Disease Market Size and Forecast (2016-2026)
6.3.4 Mexico Neurodegenerative Disease Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Neurodegenerative Disease Revenue by Type (2016-2026)
7.2 Europe Neurodegenerative Disease Revenue by Application (2016-2026)
7.3 Europe Neurodegenerative Disease Market Size by Country
7.3.1 Europe Neurodegenerative Disease Revenue by Country (2016-2026)
7.3.2 Germany Neurodegenerative Disease Market Size and Forecast (2016-2026)
7.3.3 France Neurodegenerative Disease Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Neurodegenerative Disease Market Size and Forecast (2016-2026)
7.3.5 Russia Neurodegenerative Disease Market Size and Forecast (2016-2026)
7.3.6 Italy Neurodegenerative Disease Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Neurodegenerative Disease Revenue by Type (2016-2026)
8.2 Asia-Pacific Neurodegenerative Disease Revenue by Application (2016-2026)
8.3 Asia-Pacific Neurodegenerative Disease Market Size by Region
8.3.1 Asia-Pacific Neurodegenerative Disease Revenue by Region (2016-2026)
8.3.2 China Neurodegenerative Disease Market Size and Forecast (2016-2026)
8.3.3 Japan Neurodegenerative Disease Market Size and Forecast (2016-2026)
8.3.4 South Korea Neurodegenerative Disease Market Size and Forecast (2016-2026)
8.3.5 India Neurodegenerative Disease Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Neurodegenerative Disease Market Size and Forecast (2016-2026)
8.3.7 Australia Neurodegenerative Disease Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Neurodegenerative Disease Revenue by Type (2016-2026)
9.2 South America Neurodegenerative Disease Revenue by Application (2016-2026)
9.3 South America Neurodegenerative Disease Market Size by Country
9.3.1 South America Neurodegenerative Disease Revenue by Country (2016-2026)
9.3.2 Brazil Neurodegenerative Disease Market Size and Forecast (2016-2026)
9.3.3 Argentina Neurodegenerative Disease Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Neurodegenerative Disease Revenue by Type (2016-2026)
10.2 Middle East & Africa Neurodegenerative Disease Revenue by Application (2016-2026)
10.3 Middle East & Africa Neurodegenerative Disease Market Size by Country
10.3.1 Middle East & Africa Neurodegenerative Disease Revenue by Country (2016-2026)
10.3.2 Turkey Neurodegenerative Disease Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Neurodegenerative Disease Market Size and Forecast (2016-2026)
10.3.4 UAE Neurodegenerative Disease Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Neurodegenerative Disease Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Neurodegenerative Disease Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Neurodegenerative Disease Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Neurodegenerative Disease Revenue (USD Million) by Region (2016-2021)
Table 5. Global Neurodegenerative Disease Revenue Market Share by Region (2021-2026)
Table 6. Novartis Corporate Information, Head Office, and Major Competitors
Table 7. Novartis Major Business
Table 8. Novartis Neurodegenerative Disease Product and Solutions
Table 9. Novartis Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Pfizer Corporate Information, Head Office, and Major Competitors
Table 11. Pfizer Major Business
Table 12. Pfizer Neurodegenerative Disease Product and Solutions
Table 13. Pfizer Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Merck Serono Corporate Information, Head Office, and Major Competitors
Table 15. Merck Serono Major Business
Table 16. Merck Serono Neurodegenerative Disease Product and Solutions
Table 17. Merck Serono Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Biogen Idec Corporate Information, Head Office, and Major Competitors
Table 19. Biogen Idec Major Business
Table 20. Biogen Idec Neurodegenerative Disease Product and Solutions
Table 21. Biogen Idec Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. TEVA Corporate Information, Head Office, and Major Competitors
Table 23. TEVA Major Business
Table 24. TEVA Neurodegenerative Disease Product and Solutions
Table 25. TEVA Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. UCB Corporate Information, Head Office, and Major Competitors
Table 27. UCB Major Business
Table 28. UCB Neurodegenerative Disease Product and Solutions
Table 29. UCB Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 31. Boehringer Ingelheim Major Business
Table 32. Boehringer Ingelheim Neurodegenerative Disease Product and Solutions
Table 33. Boehringer Ingelheim Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Sanofi Corporate Information, Head Office, and Major Competitors
Table 35. Sanofi Major Business
Table 36. Sanofi Neurodegenerative Disease Product and Solutions
Table 37. Sanofi Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 39. GlaxoSmithKline Major Business
Table 40. GlaxoSmithKline Neurodegenerative Disease Product and Solutions
Table 41. GlaxoSmithKline Neurodegenerative Disease Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Global Neurodegenerative Disease Revenue (USD Million) by Players (2019-2021)
Table 43. Global Neurodegenerative Disease Revenue Share by Players (2019-2021)
Table 44. Breakdown of Neurodegenerative Disease by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Neurodegenerative Disease Players Head Office, Products and Services Provided
Table 46. Neurodegenerative Disease Mergers & Acquisitions in the Past Five Years
Table 47. Neurodegenerative Disease New Entrants and Expansion Plans
Table 48. Global Neurodegenerative Disease Revenue (USD Million) by Type (2016-2021)
Table 49. Global Neurodegenerative Disease Revenue Share by Type (2016-2021)
Table 50. Global Neurodegenerative Disease Revenue Forecast by Type (2021-2026)
Table 51. Global Neurodegenerative Disease Revenue by Application (2016-2021)
Table 52. Global Neurodegenerative Disease Revenue Forecast by Application (2021-2026)
Table 53. North America Neurodegenerative Disease Revenue by Type (2016-2021) & (USD Million)
Table 54. North America Neurodegenerative Disease Revenue by Type (2021-2026) & (USD Million)
Table 55. North America Neurodegenerative Disease Revenue by Application (2016-2021) & (USD Million)
Table 56. North America Neurodegenerative Disease Revenue by Application (2021-2026) & (USD Million)
Table 57. North America Neurodegenerative Disease Revenue by Country (2016-2021) & (USD Million)
Table 58. North America Neurodegenerative Disease Revenue by Country (2021-2026) & (USD Million)
Table 59. Europe Neurodegenerative Disease Revenue by Type (2016-2021) & (USD Million)
Table 60. Europe Neurodegenerative Disease Revenue by Type (2021-2026) & (USD Million)
Table 61. Europe Neurodegenerative Disease Revenue by Application (2016-2021) & (USD Million)
Table 62. Europe Neurodegenerative Disease Revenue by Application (2021-2026) & (USD Million)
Table 63. Europe Neurodegenerative Disease Revenue by Country (2016-2021) & (USD Million)
Table 64. Europe Neurodegenerative Disease Revenue by Country (2021-2026) & (USD Million)
Table 65. Asia-Pacific Neurodegenerative Disease Revenue by Type (2016-2021) & (USD Million)
Table 66. Asia-Pacific Neurodegenerative Disease Revenue by Type (2021-2026) & (USD Million)
Table 67. Asia-Pacific Neurodegenerative Disease Revenue by Application (2016-2021) & (USD Million)
Table 68. Asia-Pacific Neurodegenerative Disease Revenue by Application (2021-2026) & (USD Million)
Table 69. Asia-Pacific Neurodegenerative Disease Revenue by Region (2016-2021) & (USD Million)
Table 70. Asia-Pacific Neurodegenerative Disease Revenue by Region (2021-2026) & (USD Million)
Table 71. South America Neurodegenerative Disease Revenue by Type (2016-2021) & (USD Million)
Table 72. South America Neurodegenerative Disease Revenue by Type (2021-2026) & (USD Million)
Table 73. South America Neurodegenerative Disease Revenue by Application (2016-2021) & (USD Million)
Table 74. South America Neurodegenerative Disease Revenue by Application (2021-2026) & (USD Million)
Table 75. South America Neurodegenerative Disease Revenue by Country (2016-2021) & (USD Million)
Table 76. South America Neurodegenerative Disease Revenue by Country (2021-2026) & (USD Million)
Table 77. Middle East & Africa Neurodegenerative Disease Revenue by Type (2016-2021) & (USD Million)
Table 78. Middle East & Africa Neurodegenerative Disease Revenue by Type (2021-2026) & (USD Million)
Table 79. Middle East & Africa Neurodegenerative Disease Revenue by Application (2016-2021) & (USD Million)
Table 80. Middle East & Africa Neurodegenerative Disease Revenue by Application (2021-2026) & (USD Million)
Table 81. Middle East & Africa Neurodegenerative Disease Revenue by Country (2016-2021) & (USD Million)
Table 82. Middle East & Africa Neurodegenerative Disease Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Neurodegenerative Disease Picture
Figure 2. Global Neurodegenerative Disease Revenue Market Share by Type in 2020
Figure 3. NMDA
Figure 4. SSRIs
Figure 5. Dopamine Inhibitors
Figure 6. Neurodegenerative Disease Revenue Market Share by Application in 2020
Figure 7. Parkinson’s Disease Picture
Figure 8. Huntington Disease Picture
Figure 9. Amyotrophic Lateral Sclerosis Picture
Figure 10. Alzheimer’s Disease Picture
Figure 11. Global Neurodegenerative Disease Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Neurodegenerative Disease Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Neurodegenerative Disease Revenue Market Share by Region (2016-2026)
Figure 14. Global Neurodegenerative Disease Revenue Market Share by Region in 2020
Figure 15. North America Neurodegenerative Disease Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Neurodegenerative Disease Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Neurodegenerative Disease Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Neurodegenerative Disease Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Neurodegenerative Disease Market Drivers
Figure 20. Neurodegenerative Disease Market Restraints
Figure 21. Neurodegenerative Disease Market Trends
Figure 22. Novartis Recent Developments and Future Plans
Figure 23. Pfizer Recent Developments and Future Plans
Figure 24. Merck Serono Recent Developments and Future Plans
Figure 25. Biogen Idec Recent Developments and Future Plans
Figure 26. TEVA Recent Developments and Future Plans
Figure 27. UCB Recent Developments and Future Plans
Figure 28. Boehringer Ingelheim Recent Developments and Future Plans
Figure 29. Sanofi Recent Developments and Future Plans
Figure 30. GlaxoSmithKline Recent Developments and Future Plans
Figure 32. Global Neurodegenerative Disease Revenue Share by Players in 2020
Figure 33. Neurodegenerative Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players Neurodegenerative Disease Revenue Market Share in 2020
Figure 35. Global Top 10 Players Neurodegenerative Disease Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global Neurodegenerative Disease Revenue Share by Type in 2020
Figure 38. Global Neurodegenerative Disease Market Share Forecast by Type (2021-2026)
Figure 39. Global Neurodegenerative Disease Revenue Share by Application in 2020
Figure 40. Global Neurodegenerative Disease Market Share Forecast by Application (2021-2026)
Figure 41. North America Neurodegenerative Disease Sales Market Share by Type (2016-2026)
Figure 42. North America Neurodegenerative Disease Sales Market Share by Application (2016-2026)
Figure 43. North America Neurodegenerative Disease Revenue Market Share by Country (2016-2026)
Figure 44. United States Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Neurodegenerative Disease Sales Market Share by Type (2016-2026)
Figure 48. Europe Neurodegenerative Disease Sales Market Share by Application (2016-2026)
Figure 49. Europe Neurodegenerative Disease Revenue Market Share by Country (2016-2026)
Figure 50. Germany Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Neurodegenerative Disease Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific Neurodegenerative Disease Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Neurodegenerative Disease Revenue Market Share by Region (2016-2026)
Figure 58. China Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Neurodegenerative Disease Sales Market Share by Type (2016-2026)
Figure 65. South America Neurodegenerative Disease Sales Market Share by Application (2016-2026)
Figure 66. South America Neurodegenerative Disease Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa Neurodegenerative Disease Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa Neurodegenerative Disease Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa Neurodegenerative Disease Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE Neurodegenerative Disease Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
世界の神経変性疾患市場規模・現状・予測（2021年-2027年） Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss. Market Analysis and Insights: Global Neurodegenerative Disease Market The global Ne…- 世界の神経変性治療薬市場 2021：企業別、地域別、種類・用途別 The Neurodegenerative Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…
- 世界の神経変性疾患治療薬市場規模・現状・予測（2021年-2027年） Neurodegenerative disease is caused by the loss of neurons and/or their myelin sheath, which worsens over time and becomes dysfunctional. Market Analysis and Insights: Global Neurodegenerative Diseases Drug Market The global Neurodegenerative Diseases Drug market size is projected to reach US$ XX m…
- 世界のアルツハイマー病治療市場規模・現状・予測（2021年-2027年） Alzheimer’s disease is a neurodegenerative, progressive, non-reversible disorder. Alzheimer’s disease is caused due to abnormal functioning of brain cells i.e. failure of synaptic transmission, resulting in the loss of cognitive functions. Some of the signs and symptoms of alzheimer’s disease are me…
- 世界のサンドホフ病治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Sandhoff Disease Therapeutics Market The global Sandhoff Disease Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integ…